RESUMO
OBJECTIVE: To establish a pharmacodynamics testing and predicting model for molecular targeted therapy of advanced hepatocellular carcinoma (HCC). METHODS: MHCC97-H (a highly aggressive HCC cell line) cells were cultured to establish: ①a subcutaneous tumor model in nude mice, ②an in situ HCC tissue seeding model, ③a hepatic portal vein injection of HCC cell model. Nude mice were intragastric admistrated with 2 mg•kg-1 of sorafenib, apatinib or anlotinib per two days. The antitumor effect of sorafenib, apatinib and anlotinib was examined. RESULTS: Sorafenib, apatinib and anlotinib could significantly inhibit the growth of HCC cells in different models, and the effect of apatinib and anlotinib was better than that of sorafenib. CONCLUSION: By establishing tumor models of HCC in nude mice, this work provides a strategy to examine the potential antitumor activation of agents for advanced HCC.